Author: Musser, Margaret L. ; McNiel, Elizabeth A. ; Clifford, Craig A. ; McAnulty, Lydia C. Cook ; Johannes, Chad M. ; Bergman, Philip J. ; Treml, Laura S.

AbstractBackgroundCanine peripheral nodal T‐cell lymphoma is considered chemotherapy resistant and carries a relatively poor prognosis. Prospective evaluations reporting the impact of chemotherapy on progression‐free survival (PFS) and overall survival time for dogs with T‐cell lymphoma are lacking. This study examined the impact of L‐CHOP (L‐asparaginase, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy or L‐CHOP in combination with AT‐005, a US Department of Agriculture‐licensed caninised monoclonal antibody, on PFS and response rates in dogs with clinical intermediate‐ and high‐grade peripheral nodal T‐cell lymphoma.MethodsA prospective, randomised, placebo‐controlled, investigator‐ and owner‐blinded, multicentre study was completed. All dogs received a 19‐week L‐CHOP chemotherapy protocol with randomisation (1:1) into placebo or AT‐005 groups. Response was evaluated via the Veterinary Cooperative Oncology Group criteria for canine lymphoma.ResultsForty‐nine dogs were enrolled (25 received placebo and 24 received AT‐005). Most demographic factors were similar between the two groups, with the exception that more dogs with stage IV and V disease were treated with AT‐005 (34% vs. 8%; p = 0.03). Median PFS was 103 days (95% confidence interval [CI], 56–118) in the placebo group versus 64 days (95% CI, 36–118) in the AT‐005 group. The overall response rate (ORR) for all dogs was 98% (48 of 49); complete response rate in the placebo group (64%) was not different from the AT‐005 group (67%).ConclusionsTo the best of the authors’ knowledge, this is the first prospective study to document that treatment with L‐CHOP chemotherapy, with or without AT‐005, may result in a high ORR, but relatively brief PFS in dogs with clinical intermediate‐ and high‐grade T‐cell lymphoma.

100 Deals associated with Tamtuvetmab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tamtuvetmab	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Preclinical	US	Arctic TherapeuticsStartup	05 Sep 2023
Rhinovirus infection	Preclinical	US	Arctic TherapeuticsStartup	05 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis